【ChiCTR2600118687】Effects of nature-based mindfulness training on depression among adults with childhood adversity: A randomised controlled trial
ChiCTR2600118687
尚未开始
/
/
/
2026-02-10
/
/
Depression awith childhood adversity
Effects of nature-based mindfulness training on depression among adults with childhood adversity: A randomised controlled trial
Effects of nature-based mindfulness training on depression among adults with childhood adversity: A randomised controlled trial
Objectives: 1. PInvestigate the effect of Nature-based Mindfulness Training (NBMT) on reducing depressive symptoms among adults with depression and adverse childhood experiences (ACE). 2.Investigate the effect of NBMT on reducing anxiety symptoms and improving quality of life among adults with depression and ACE. 3.Compare the effects of NBMT with MBCT in reducing depressive and anxiety symptoms and improving quality of life . 4.Examine adherence and rumination as potential mediators responsible for better outcomes in NBMT.
随机平行对照
其它
The method of sampling will be stratified randomisation based on sex and psychiatric medication use to achieve demographic balance between the two arms. An experienced independent statistician will generate the randomisation sequence using computer-generated random results.
The research staff member who conducts the assessments or statistical analyses will be blinded to the group assignments.
General Research Fund
/
128
/
2026-02-16
2028-02-16
/
1) Aged 18 years or above 2) Screened by the Patient Health Questionnaire depression scale (PHQ-9) with at least moderate depressive symptoms (i.e. a PHQ score of 10 or above) 3) ACE histories will be collected using the Adverse Childhood Experiences—International Questionnaire (ACE-IQ) with at least one ACE;
请登录查看1) The presence of serious suicidal risk 2) Severe medical illness with a prognosis of less than 6 months to live 3) A diagnosis of antisocial, schizotypal, or borderline personality disorder; 4) A history of schizophrenia, schizoaffective disorder, bipolar disorder, substance abuse, or organic brain disorders.;
请登录查看香港中文大學賽馬會公共衛生及基層醫療學院
/
香港中文大學賽馬會公共衛生及基層醫療學院的其他临床试验
香港中文大學賽馬會公共衛生及基層醫療學院的其他临床试验
最新临床资讯
-
瑞吉生物mRNA个性化肿瘤疫苗RH125临床试验申请获CDE受理
瑞吉生命科技2026-10-15
-
7 款 FDA 药物、50+ 临床候选:FBDD 为什么能啃下 KRAS、BRAF 这些"不可成药"靶点?
MCE 抑制剂2026-10-15
-
药智数据2026-10-15
-
生物技术小编2026-10-15
-
宜明昂科2026-10-15
-
泽维生物2026-10-15
-
医药笔记2026-10-15
-
劲方医药GenFleet2026-10-15
-
药明康德2026-10-15
-
国际肿瘤医讯2026-10-14
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-10-16
-
2026-10-16
-
2026-10-16
-
摩熵咨询 33 41
-
摩熵咨询 20 0
-
摩熵咨询 20 8
-
颁布机构:国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构:国家药品监督管理局 2026-09-10
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-10-19
-
2026-10-17
-
2026-10-16
-
摩熵咨询 35 78
-
摩熵咨询 28 65
-
摩熵咨询 34 45
-
颁布机构:国家市场监督管理总局 2026-10-16
-
颁布机构:国家市场监督管理总局 2026-09-30
-
颁布机构:国家市场监督管理总局 2026-09-29
